Myomo® Announces New Distribution Agreement for Australia / New Zealand
01 May 2019 - 10:00PM
Business Wire
Neuro Muscular Orthotics to Offer
MyoPro® Across a Huge New Geography
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company that offers increased
functionality for those suffering from neurological disorders and
upper limb paralysis, today announced that it has signed an
agreement with NeuroMuscular Orthotics Pty Ltd (NMO) with the goal
of offering MyoPro across Australia and New Zealand.
NMO is the leading Australian specialist in facilitating optimal
orthotic care of individuals with long term functional impairment
as a result of neurological and orthopedic pathologies. The company
achieves this through direct clinical service provision to its own
clients in Melbourne and Sydney, and through its sister clinic
Interface Orthotics in Perth. In addition, NeuroMuscular Orthotics
expands its reach throughout Australia and New Zealand by offering
distribution, central fabrication and education to certified
orthotist/prosthetists.
Darren Pereira, NMO Director, explains, “NeuroMuscular Orthotics
is excited to be partnering with the passionate and innovative team
at Myomo to bring the MyoPro powered orthosis to Australia and New
Zealand. As the only product of its kind, the MyoPro will unlock
new possibilities for many Australians and New Zealanders with
upper limb impairment, aiding in their social and economic
participation, helping them to achieve their goals and live an
ordinary life.”
Myomo and NMO launched MyoPro across Australia with a
comprehensive joint roadshow, visiting Brisbane, Melbourne,
Adelaide, Perth, Sydney and Gold Coast. Together, the team trained
25 orthotics and prosthetics clinicians, evaluated 30 potential
MyoPro patients and trained allied rehabilitation physicians,
physiotherapists and occupational therapists.
Paul R. Gudonis, Chairman and CEO of Myomo, said, “NMO is one of
the strongest technical orthotics providers in one of the strongest
economies in the Pacific region. It is an honor to call them a
partner, and we look forward to offering MyoPro to the tens of
thousands of Australians suffering a paralyzed arm from stroke,
nerve injury of other neuromuscular disease.”
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
support the arm and restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. and representatives internationally. For more
information, please visit www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company's future business expectations which are subject to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but are not
limited to, our collaboration with NeuroMuscular Orthotics and
plans for offering our MyoPro product in Australia and New Zealand.
These forward-looking statements are only predictions and may
differ materially from actual results due to a variety of factors.
Our actual results could differ materially from those anticipated
in these forward looking statements for many reasons, including,
without limitation, risks related to regulatory approval and market
acceptance of our products, our ability to secure and maintain
reimbursement for our products, our ability to obtain additional
funding to sustain and grow our business, and the other risk
factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that
potentially could affect Myomo's business and financial results is
included in Myomo's filings with the Securities and Exchange
Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only
as of the date made. The Company disclaims any obligation
subsequently to revise any forward-looking statements to reflect
events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190501005064/en/
Investor Relations:Vivian CervantesPCG
Advisory646-863-6274vivian@pcgadvisory.comPublic
Relations:Sarah KarrMatter
Communications978-518-4817myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2024 to May 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From May 2023 to May 2024